Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Pantec Biosolutions appoints new Board members
New appointments are set to enhance future business and finance strategies


Ruggell, Liechtenstein, 15 May 2008, Pantec Biosolutions AG, a privately-owned company developing innovative technologies for transdermal drug delivery, today announces the appointment of Burkhard Feurstein and Michael Armbruester to the Board following their election at the annual shareholders meeting held on April 24, 2008.

Mr Feurstein is Director of Finance at Gamma Capital Partners AG (GCP), a venture capital investment company. He has over 20 years expertise in investment and project finance, including a decade of direct and fund investment experience. Prior to GCP, Mr Feurstein was Managing Director of Vienna-based venture capitalists, Invest Equity, specialising in early stage technology companies. In 1990, he initiated and implemented the government-sponsored capital guarantee scheme (AWS), helping to kick-start the Austrian venture capital industry. His core expertise lies in finance and turn-around management with operative experience as an industrial manager in the biopharmaceuticals and medical technology industries. Mr Feurstein has a M.S. degree in theoretical physics from Vienna Technical University.

Mr Feurstein commented, 'I am very excited to join Pantec Biosolutions’ world-class team. I look forward to contributing towards the Company’s continued success and to cement its status as one of the cutting edge life science companies that this region is famous for.'

Michael Armbruester graduated from the University of Evansville in the U.S. with a Bachelor of Science degree in international business in 1986. Post graduation, he worked for one of the world's largest Swiss based commodity houses. After his initial training, Mr Armbruester rose to become a senior trader, with postings in Australia, Hong Kong, Switzerland and the United States, a senior partner and was made head of the Company’s aluminium operations for both North and South America. He was also extensively involved in the acquisition of three aluminium manufacturing facilities and served as President for each. At their peak, these companies employed in excess of 2500 staff. Mr Armbruester has held numerous Board positions, developing a network of contacts in the venture capital and hedge fund sectors. He formed JB Commodities in early 2005. In just three years, the Company, which specialises in physical commodity trading and financial futures, has established four offices in four countries and is headquartered in Switzerland.

Mr Armbruester commented: “It is a privilege to have been given the chance to serve on the Board of Pantec Biosolutions and to support its experienced management team. The company has brilliant concepts, a very bright future and it is exciting to help them in achieving their strategic objectives”.

Christof Boehler, CEO and Board member said: “We are delighted to have Burkhard Feurstein and Michael Armbruester on board since they both bring substantial expertise in corporate finance, management and mergers and acquisitions. With the addition of their skills, we are ideally positioned to plan the Company’s future finance and business strategy especially with regard to our target financial exit strategy, an IPO.

- Ends -

About Pantec Biosolutions and P.L.E.A.S.E.®

Pantec Biosolutions is a private drug delivery company specialised in using laser microporation technology to deliver large molecular weight drugs into the epidermis for local or systemic uptake. Its proprietary P.L.E.A.S.E.® (Painless Laser Epidermal System) platform enables efficient, needle-free and painless administration of biopharmaceutical drugs, in varying and individualised dosages, through partnered patch technology. The technology is currently in clinical trials for the delivery of IVF hormone therapy, a market with an estimated value of US$ 1.5 – 2 billion.

The Company’s P.L.E.A.S.E.® platform is available both for the development of the Company’s own pipeline and for penetration into new markets through strategic partnerships.


Publisher Contact Information:

College Hill Life Sciences
+44 (0) 20 7457 2020
pantec@collegehill.com

Company profile of Pantec Biosolutions
Past press releases of Pantec Biosolutions.

Data


25,720
Tech investments
From our Online Data Service
16,652
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
May 17€4.0MBiopharmaceuticals
May 16€15.0MPayment software
May 16€4.0MInternet services
May 16€80.0MConsumer electronics
May 16€6.3MImaging
May 16€13.0MInternet services
May 16€34.5MBiotechnology

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

Aug 17
Komed Health
komed health closes seed financing round





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.